Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
6.14M
-
Number of holders
-
28
-
Total 13F shares, excl. options
-
2.81M
-
Shares change
-
+139K
-
Total reported value, excl. options
-
$1.85M
-
Value change
-
-$7.73K
-
Number of buys
-
11
-
Number of sells
-
-10
-
Price
-
$0.66
Significant Holders of QUALIGEN THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (QLGN) as of Q1 2022
38 filings reported holding QLGN - QUALIGEN THERAPEUTICS, INC. - Common Stock, par value $0.001 per share as of Q1 2022.
QUALIGEN THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (QLGN) has 28 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.81M shares
of 6.14M outstanding shares and own 45.75% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (1.17M shares), BlackRock Inc. (335K shares), GEODE CAPITAL MANAGEMENT, LLC (213K shares), PRICE T ROWE ASSOCIATES INC /MD/ (129K shares), CITADEL ADVISORS LLC (124K shares), RENAISSANCE TECHNOLOGIES LLC (114K shares), STATE STREET CORP (105K shares), COMMONWEALTH EQUITY SERVICES, LLC (87.5K shares), FRANKLIN RESOURCES INC (82K shares), and HighMark Wealth Management LLC (80.1K shares).
This table shows the top 28 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.